Cover Image
市場調查報告書

甲狀腺髓質癌:開發中產品分析

Medullary Thyroid Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229769
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
甲狀腺髓質癌:開發中產品分析 Medullary Thyroid Cancer - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 100 Pages
簡介

甲狀腺髓質癌是由甲狀腺濾泡旁細胞發病的甲狀腺癌之一。濾泡旁細胞會分泌抑鈣素這個荷爾蒙。抑鈣素是和副甲狀腺素 (甲狀旁腺細胞所分泌的蛋白質荷爾蒙) 一起作用,來調節體內鈣濃度的。甲狀腺髓質癌的症狀和甲狀腺癌的其他型態相似。常見有肉眼可見的疙瘩、吞嚥時的有塊狀物感、聲音嘶啞,淋巴節腫大等症狀。治療方法有化療,外科手術,生物學療法,放射線治療等選擇。

本報告提供甲狀腺髓質癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

甲狀腺髓質癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

研究中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • AbbVie Inc
  • Advenchen Laboratories, LLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Hutchison MediPharma Limited
  • Immunomedics, Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Pfizer Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8369IDB

Summary

Global Markets Direct's, 'Medullary Thyroid Cancer - Pipeline Review, H2 2016', provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
  • The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Medullary Thyroid Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Medullary Thyroid Cancer - Overview
    • Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis
  • Medullary Thyroid Cancer - Therapeutics under Development by Companies
  • Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
  • Medullary Thyroid Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Medullary Thyroid Cancer - Products under Development by Companies
  • Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes
  • Medullary Thyroid Cancer - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Advenchen Laboratories, LLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • Hutchison MediPharma Limited
    • Immunomedics, Inc.
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
    • Pfizer Inc.
  • Medullary Thyroid Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-3818 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLM-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLM-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLM-94 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GI-6207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMS-616 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • regorafenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rovalpituzumab tesirine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temsirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Medullary Thyroid Cancer - Dormant Projects
  • Medullary Thyroid Cancer - Discontinued Products
  • Medullary Thyroid Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Medullary Thyroid Cancer, H2 2016
  • Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Medullary Thyroid Cancer - Pipeline by AbbVie Inc, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Bayer AG, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H2 2016
  • Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
  • Medullary Thyroid Cancer - Pipeline by Novartis AG, H2 2016
  • Medullary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Medullary Thyroid Cancer - Dormant Projects, H2 2016
  • Medullary Thyroid Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Medullary Thyroid Cancer, H2 2016
  • Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top